Phenazopyridine

Introduction Overview

Generic Name

phenazopyridine

Brand Name

AZO Urinary Pain Relief, AZO Urinary Pain Relief Max Strength, Azo-Standard, Baridium, Prodium, Pyridium, Uricalm, Urinary Pain Relief Maximum Strength, Uristat, Uristat Ultra, Azo-Gesic, Re-Azo, Viridium, Eridium, Pyridiate, Urogesic, Phenazo, Urodol, Urinary Analgesic, Uro-Pain Maximum Strength, Uro-Pain

Dosage Form

oral tablet (100 mg; 200 mg; 95 mg; 97.2 mg; 97.5 mg; 99.5 mg)

Drug Class

Miscellaneous genitourinary tract agents

Pharmacokinetics

Absorption:
Phenazopyridine is rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically achieved within 2 to 3 hours post-dose. Its absorption can be influenced by the presence of food; hence, administration after meals is advised to enhance gastrointestinal tolerability rather than absorption per se. The drug exhibits appreciable bioavailability, which supports once to thrice-daily dosing regimens.

Distribution:
Once absorbed, phenazopyridine is moderately bound to plasma proteins, which affects its distribution volume. It exhibits preferential distribution to the urinary tract tissues, particularly concentrating in the mucosa of the lower urinary tract such as the bladder and urethra, which is central to its localized analgesic effects. Phenazopyridine’s lipophilicity facilitates its penetration into these tissues, enabling symptomatic relief of urinary tract discomfort. The volume of distribution and tissue affinity support the rationale for targeted urinary analgesia.

Metabolism:
Phenazopyridine undergoes hepatic metabolism primarily through azo-reduction and conjugation pathways. It is metabolized into several inactive metabolites. The metabolic rate may be influenced by hepatic function, and patients with liver impairment may experience altered clearance. Furthermore, patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may have a predisposition to hemolytic events due to phenazopyridine metabolites, necessitating caution.

Elimination:
The elimination of phenazopyridine and its metabolites is predominantly renal. Approximately 80-90% of the administered dose is excreted unchanged or as metabolites in the urine within 24 hours. This renal excretion accounts for the drug’s direct action on the lower urinary tract. Renal function significantly impacts drug clearance; consequently, phenazopyridine is contraindicated in patients with significant renal impairment or kidney disease due to potential drug accumulation and toxicity risks. The drug’s elimination half-life is approximately 7 to 8 hours, justifying the typical thrice-daily dosing.

Dosage Forms

Available Dosage Forms:
Phenazopyridine is available exclusively as oral tablets in multiple strengths to accommodate varying clinical needs. Specific tablet strengths include 95 mg, 97.2 mg, 97.5 mg, 99.5 mg, 100 mg, and 200 mg. These formulations provide flexibility in dosing, enabling both standard and max-strength regimens.

Dosages for Adults and Adolescents:
For adults and adolescents aged 12 years and older, the recommended dose for symptomatic relief of dysuria is 190 to 200 mg taken orally three times a day after meals. Administration with a full glass of water is advised to promote adequate drug absorption and minimize gastrointestinal discomfort. Therapy duration should not exceed two days concurrently with antibacterial treatments due to the absence of evidence for enhanced benefit beyond this period.

Specific Patient Populations:
Use in patients with renal impairment is contraindicated because renal dysfunction may lead to accumulation of phenazopyridine and increased toxicity risk. Caution is advised in patients with hepatic impairment, diabetes mellitus, or G6PD deficiency due to alterations in drug metabolism and risk for adverse effects such as hemolytic anemia. Phenazopyridine falls under FDA pregnancy category B; although not expected to cause harm to the fetus, use during pregnancy should only be considered after risk-benefit evaluation by a healthcare provider. The safety profile during breastfeeding is not well established, hence phenazopyridine should be administered to nursing mothers only under medical supervision.

Mechanism Of Action

Phenazopyridine is a urinary tract analgesic which primarily exerts its effect through a topical action on the mucosa of the lower urinary tract including the bladder and urethra. The drug’s molecular mechanism involves direct local analgesic effects without systemic anti-inflammatory or antimicrobial activity. This localized action is believed to result from the drug’s azo structure allowing it to exert a mild anesthetic effect through reducing irritation of the mucosal lining.

At a cellular level, phenazopyridine stabilizes the bladder epithelium and reduces the sensitivity of the local sensory nerves that transmit pain signals associated with urinary tract irritation. Though not fully elucidated, the drug may inhibit peripheral nerve transmission by modulating ion channels associated with pain perception in the urothelial tissues.

Biochemically, phenazopyridine does not inhibit enzymes or prostaglandin synthesis, distinguishing it from nonsteroidal anti-inflammatory drugs or antibiotics. Instead, its metabolite profile and azo dye properties facilitate a staining effect, which correlates with its accumulation in urinary tract tissues and thus its analgesic properties.

Clinically, phenazopyridine provides symptomatic relief of dysuria, urgency, frequency, and pain originating from urinary tract irritation caused by infection, trauma, surgery, catheterization, or instrumentation. It is used adjunctively with appropriate antibacterial agents to alleviate discomfort during urinary tract infections but has no antibacterial effects itself. Comparative studies emphasize that phenazopyridine's therapeutic role is supportive symptom control rather than curative, reinforcing the need for concomitant antimicrobial therapy where indicated.

Pharmacological Actions

Acts as a topical analgesic on the urinary tract mucosa relieving pain and burning sensations.
Reduces urinary urgency and frequency by decreasing mucosal irritation.
Exerts a localized anesthetic effect without systemic anti-inflammatory activity.
Does not possess antimicrobial properties and thus does not treat urinary infections.
Rapid onset of analgesic effect within hours of administration.
Concentrates in the urinary tract tissues, especially the bladder and urethra.
Dye properties lead to discoloration of urine, indicating renal excretion.
Minimal systemic absorption beyond urinary tract targeting.
Metabolized hepatically with renal excretion of metabolites.
Supports symptom management in urinary tract trauma, surgery, and catheterization.
Useful adjunct to antibiotic therapy for urinary tract infections.
Effective for irritation caused by endoscopic procedures and passage of catheters or sounds.
Lacks impact on inflammatory mediators involved in urinary tract infection.
Provides symptomatic relief of dysuria across adult and adolescent populations.
Not recommended for prolonged use beyond 2 days without medical supervision.

Therapeutic Or Clinical Uses

Symptomatic relief of pain, burning, urgency, frequency, and discomfort due to irritation of the lower urinary tract mucosa.
Adjunctive relief during urinary tract infections alongside appropriate antibiotic therapy.
Management of urinary symptoms associated with urinary tract trauma.
Post-surgical urinary tract symptom relief to improve patient comfort.
Relief of dysuria related to catheterization and instrumentation procedures.
Treatment of urinary tract irritation caused by passage of sounds or catheters.
Symptomatic control in interstitial cystitis (as supportive care, not curative).
Temporary relief of urinary symptoms due to bladder irritation from non-infectious causes.
Alleviation of urinary discomfort associated with bladder surgery or instrumentation.
Management of increased urinary urgency and frequency linked to irritation.
Used in patients experiencing urinary symptoms without confirmed infection.
Supportive therapy during diagnostic endoscopic procedures of the urinary tract.
Short-term therapy intended for symptomatic control rather than infection eradication.
Relieves lower urinary tract symptoms in both adult and adolescent patients aged 12 years and older.
Helps improve quality of life by mitigating urinary discomfort in clinical settings.

Side Or Adverse Effects

Headache occurring in some individuals possibly due to systemic absorption.
Dizziness reported commonly, necessitating caution during activities requiring alertness.
Gastrointestinal upset including nausea and stomach discomfort.
Potential allergic reactions such as hives, swelling, and breathing difficulties.
Rare but serious adverse effects including decreased urine output or anuria.
Signs of hypersensitivity like swelling of lips, tongue or throat.
Confusion or altered mental status especially in elderly or predisposed patients.
Symptoms of hemolytic anemia in patients with G6PD deficiency.
Yellowing of skin or sclera indicating potential hepatic involvement or jaundice.
Fever coupled with abdominal pain suggesting possible systemic toxicity.
Bluish or purplish discoloration of the skin indicative of methemoglobinemia or cyanosis.
Urine discoloration to orange or red, a normal but potentially staining effect.
Permanent staining of soft contact lenses if worn during therapy.
Rare risk of renal toxicity in patients with pre-existing kidney disease.
Potential interference with laboratory urine tests, producing unusual results.

Precautions

Avoid use in patients with known allergy to phenazopyridine or related compounds.
Contraindicated in patients with kidney disease due to risk of toxicity and accumulation.
Use caution in patients with liver disease given hepatic metabolism of the drug.
Screen for G6PD deficiency to prevent risk of hemolytic anemia before initiation.
Avoid prolonged use beyond two days without medical supervision when taken with antibiotics.
Inform patients about the normal discoloration of urine and potential staining of clothing and contact lenses.
Exercise caution in diabetic patients due to potential altered pharmacokinetics.
Advise patients not to wear soft contact lenses during therapy as permanent staining may occur.
Avoid use during pregnancy unless clearly needed and prescribed by a physician.
Use caution when administering to breastfeeding mothers pending medical advice.
Monitor renal and hepatic function during treatment if used for extended periods.
Instruct patients to maintain adequate hydration to facilitate drug elimination.
Warn against self-medication and encourage consultation with healthcare providers for symptomatic management.
Inform patients about potential interference with urine diagnostic tests and ensure clinicians are aware of therapy.
Use with caution in elderly patients given increased risk of adverse CNS effects like dizziness and confusion.

Warnings

Do not use phenazopyridine in patients with kidney disease due to risk of accumulation and serious adverse effects.
Stop using immediately and seek medical attention if signs of allergic reaction occur (hives, difficulty breathing, facial swelling).
Do not exceed two days of use concomitantly with an antibacterial agent unless directed by a healthcare professional.
Phenazopyridine may cause urine discoloration to orange or red, which is harmless but may stain fabrics and contact lenses.
Avoid use in patients with known glucose-6-phosphate dehydrogenase (G6PD) deficiency to prevent hemolytic anemia.
Use caution in patients with liver impairment as metabolism may be altered.
Pregnancy use only if clearly needed and prescribed by a physician; safety has not been firmly established in breastfeeding.
Potential CNS side effects include headache, dizziness, and confusion; caution when operating machinery or driving.
Discontinue use if decreased urination, swelling, or rapid weight gain occur, signaling possible renal or systemic toxicity.
Phenazopyridine can interfere with urine tests, necessitating disclosure of use to healthcare providers and laboratory personnel.
Patients should avoid wearing soft contact lenses during treatment due to risk of permanent staining.
Overdose can result in serious toxicity necessitating urgent medical intervention.
Monitor for signs of jaundice or other hepatic dysfunction during therapy.
Use caution in pediatric patients 12 years and older with appropriate dosing and medical supervision.
Avoid off-label or unapproved prolonged use due to lack of safety and efficacy data.

Contraindication

Known hypersensitivity or allergy to phenazopyridine or azo compounds.
Patients with renal impairment or any form of kidney disease.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of hemolytic anemia.
Use in neonates and children under 12 years of age due to insufficient safety data.
Concurrent use beyond two days with antibiotics without explicit medical guidance.
Pregnant patients without physician approval, especially in the absence of compelling clinical indications.
Patients wearing soft contact lenses during therapy due to staining risk.
Severe hepatic impairment without careful monitoring.
Patients with unexplained urinary tract symptoms until infection and diagnosis are confirmed.
Known methemoglobinemia or conditions predisposing to cyanosis.
History of adverse reactions to phenazopyridine including severe skin reactions.
Patients with porphyria or other enzyme disorders affecting drug metabolism.
Use in patients with undiagnosed hemolytic anemia or blood dyscrasias without evaluation.
Patients receiving diagnostic urine tests where phenazopyridine interference is contraindicated.
Concurrent use with other azo dyes or systemic azo drugs without medical supervision.

Drug Interactions

May interact with antibiotics used concurrently; phenazopyridine should not be used for more than two days concomitantly due to lack of added benefit.
Potential interference with urine diagnostic assays, including glucose, bilirubin, ketones, and leukocytes test results.
Caution when used with drugs metabolized by hepatic conjugation pathways due to possible competition.
No significant cytochrome P450 interactions reported but cautious monitoring advised in polypharmacy.
May increase risk of CNS side effects such as dizziness when combined with sedatives or CNS depressants.
Incompatible with soft contact lenses; phenazopyridine can permanently stain lenses.
No direct interaction reported with common over-the-counter analgesics but caution advised.
No known significant interaction with common diabetic medications but glucose levels should be monitored due to underlying disease.
Potential pharmacodynamic interaction with drugs causing urinary retention; monitor urinary symptoms carefully.
No evidence of interaction with vitamins or herbal supplements, but clinical caution is always warranted.
Concomitant use with medications affecting renal function should be carefully evaluated.
No clinically significant interactions with antihypertensive or cardiovascular drugs documented.
Phenazopyridine may falsely alter laboratory test results, leading to misinterpretation of other drug effects.
No data suggesting interference with anticoagulants; however, bleeding risk associated with UTIs should be monitored.
No interaction with contraceptives reported, but always evaluate patient-specific medication regimens.

Preparations Of The Drug

Oral tablets available in multiple strengths: 95 mg, 97.2 mg, 97.5 mg, 99.5 mg, 100 mg, and 200 mg.
Over-the-counter formulations include both regular and maximum strength variants (e.g., AZO Urinary Pain Relief Max Strength).
Combination products containing phenazopyridine along with analgesics or antibacterial agents are available but phenazopyridine itself acts only as an analgesic.
Unit dose packaging to promote adherence to short-term therapy regimens typically not exceeding two days of use.
Brand names include Pyridium, Azo-Standard, Uricalm, Baridium, Urinary Analgesic, Uristat, and others facilitating diverse prescribing options.
Formulations are intended strictly for oral use; no injectable, topical, or suppository forms are available.
Manufactured under strict regulatory standards ensuring purity, potency, and safety compliant with FDA guidelines.
Packaging includes clear warnings about urine discoloration, contact lens staining, and contraindications for kidney disease.
Available as prescription and over-the-counter (OTC) depending on regional regulatory approvals.
Presentations designed for adult and adolescent use, with dosing instructions clearly indicated.
Generic versions widely available facilitating cost-effective therapy.
Formulations typically supplied in blister packs, bottles, or unit dose strips for convenience.
Accompanying patient information leaflets provide guidance on use, contraindications, and side effects.
No currently approved liquid or pediatric formulations for children under 12 years.
Some preparations marketed specifically for urinary pain relief with branding emphasizing symptom control.